Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
United States
City of Hope - Duarte, Duarte, California City of Hope - Lennar, Irvine, California University of Colorado Anschutz Medical Campus, Aurora, Colorado Mayo Clinic Jacksonville, Jacksonville, Florida Sylvester Cancer Center - U Miami, Miami, Florida Moffitt Cancer Center, Tampa, Florida Emory Winship Cancer Institute, Atlanta, Georgia University of Michigan, Ann Arbor, Michigan Mayo Clinic Rochester, Rochester, Minnesota Washington University St.Louis, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York Icahn School of Medicine at Mount Sinai, New York, New York Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina Gabrail Cancer Center Research, Canton, Ohio Cleveland Clinic, Cleveland, Ohio The Ohio State University, Columbus, Ohio Oregon Health and Science University, Portland, Oregon Sargon Research - Pennsylvania Cancer Specialists and Research Center, Gettysburg, Pennsylvania University of Pennsylvania, Philadelphia, Pennsylvania MD Anderson, Houston, Texas University of Washington, Seattle, Washington Medical College of Wisconsin, Milwaukee, Wisconsin Australia
Linear Clinical Research, Nedlands